A Molecularly Engineered Antiviral Banana Lectin Inhibits Fusion and is Efficacious Against Influenza Virus Infection in Vivo by Covés-Datson, Evelyn M. et al.
A molecularly engineered antiviral banana lectin
inhibits fusion and is efficacious against
influenza virus infection in vivo
Evelyn M. Covés-Datsona,b,1, Steven R. Kingc,d,1, Maureen Legendrec,1, Auroni Guptac,1, Susana M. Chand,e,1,
Emily Gitlinc,1, Vikram V. Kulkarnif, Jezreel Pantaleón Garcíaf, Donald F. Smeeg, Elke Lipkad, Scott E. Evansf,
E. Bart Tarbetg, Akira Onob,2, and David M. Markovitzc,e,h,i,3
aMedical Scientist Training Program, University of Michigan, Ann Arbor, MI 48109; bDepartment of Microbiology & Immunology, University of Michigan,
Ann Arbor, MI 48109; cDivision of Infectious Diseases, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109; dTherapeutic Systems
Research Laboratories, Inc., Ann Arbor, MI 48108; eCellular and Molecular Biology Program, University of Michigan, Ann Arbor, MI 48109; fDivision of
Internal Medicine, Department of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030; gAnimal, Dairy and Veterinary
Sciences Department, Utah State University, Logan, UT 84322; hGraduate Program in Immunology, University of Michigan, Ann Arbor, MI 48109; and iCancer
Biology Program, University of Michigan, Ann Arbor, MI 48109
Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved December 19, 2019 (received for review September 8, 2019)
There is a strong need for a new broad-spectrum antiinfluenza
therapeutic, as vaccination and existing treatments are only moder-
ately effective. We previously engineered a lectin, H84T banana lectin
(H84T), to retain broad-spectrum activity against multiple influenza
strains, including pandemic and avian, while largely eliminating the
potentially harmful mitogenicity of the parent compound. The amino
acid mutation at position 84 from histidine to threonine minimizes
the mitogenicity of the wild-type lectin while maintaining antiin-
fluenza activity in vitro. We now report that in a lethal mouse model
H84T is indeed nonmitogenic, and both early and delayed therapeu-
tic administration of H84T intraperitoneally are highly protective, as
is H84T administered subcutaneously. Mechanistically, attachment,
which we anticipated to be inhibited by H84T, was only somewhat
decreased by the lectin. Instead, H84T is internalized into the late
endosomal/lysosomal compartment and inhibits virus–endosome fu-
sion. These studies reveal that H84T is efficacious against influenza
virus in vivo, and that the loss of mitogenicity seen previously in
tissue culture is also seen in vivo, underscoring the potential utility
of H84T as a broad-spectrum antiinfluenza agent.
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Influenza viruses pose a major threat to public health world-wide, causing both seasonal epidemics, which infect millions
and kill ∼500,000 people annually, and pandemics, which are un-
predictable and have the potential to kill millions, as was illustrated
most recently in 2009 with the “swine flu” pandemic and most
dramatically in 1918 with the emergence of the “Spanish flu” that
resulted in 50 million deaths. Unfortunately, current prevention
and treatment modalities, although helpful, suffer from distinct
limitations and are at best only moderately effective. Although it
clearly reduces both the number and severity of cases, vaccination
is often underutilized and its effectiveness varies from year to year
(1). Effectiveness was estimated in the 2017 to 2018 United States
season to be only ∼25% against influenza A subtype H3N2 viruses,
which comprised ∼69% of infections (2).
At present, although there are a number of antiinfluenza agents
currently in phase II or III clinical trials (3), only three classes of
drugs are approved to treat influenza virus infection in the United
States: Adamantanes, neuraminidase (NA) inhibitors, and as of
October 2018, a new class with the sole member baloxavir mar-
boxil, a cap-dependent endonuclease protein inhibitor (4). Ada-
mantanes are obsolete in practice due to overwhelmingly high
levels of resistance to them among circulating influenza A strains
and due to their intrinsic inactivity against influenza B strains. The
current standard of care treatment is oseltamivir, a member of the
NA inhibitor class. Oseltamivir is associated with a moderate de-
crease in mortality among adults hospitalized for influenza, but it
must be initiated within 48 h of illness onset to be effective and
only shortens the duration of symptoms by about 1 d in otherwise
healthy adults (5, 6). Although oseltamivir resistance among cir-
culating strains has generally been low since the emergence of the
2009 pandemic H1N1, resistance does occur and can be high in
certain seasons (5, 7).
With the twin threats of another influenza pandemic and
emergence of antiviral resistance ever present and a paucity of
new classes of antiinfluenza drugs introduced since the NA in-
hibitors in 1999, there is a strong unmet need for new antiin-
fluenza therapeutics, particularly ones that are broad-spectrum
given the high genetic and antigenic diversity of influenza. Lec-
tins, or carbohydrate-binding proteins, have been proposed as
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potential antiviral agents due to their propensity to specifically
bind the types of glycans present at high densities in glycoproteins
on the surfaces of viruses. Indeed, influenza viruses are potential
targets of lectins because they possess two major glycoproteins,
hemagglutinin (HA) and NA, which mediate key steps of the viral
life cycle, including attachment to sialic acid-containing cellular
receptors and fusion of the viral membrane with the endosomal
membrane (HA), assembly of new virus particles (HA and NA)
(8–10), and release of virus particles by cleavage of sialic acid
residues (NA). However, the development of lectins for clinical
use has been limited by their mitogenicity and hence potential for
inflammatory side effects (11).
We have previously demonstrated that mitogenicity can be
removed from a banana lectin (BanLec), while maintaining
broad-spectrum antiviral activity, by engineering a single amino
acid mutation at position 84 from histidine to threonine (H84T
BanLec, H84T) (12). H84T is highly efficacious against pan-
demic, epidemic, and avian influenza in vitro and against lethal
influenza virus infection in vivo when administered intranasally,
yet its safety and efficacy via other clinically important routes of
administration remain to be determined. In addition, although
H84T is known to bind high-mannose type N-glycans, these
glycans are abundantly present on both HA and NA (13), and
thus it is not clear whether HA or NA is the key viral component
antagonized by H84T. We therefore set out to determine the
efficacy of systemically and subcutaneously delivered H84T, as
well as the mechanism of action of H84T. Here, we report that in
a lethal mouse model, H84T is indeed nonmitogenic as predicted
by the in vitro data, and both early and delayed therapeutic
administration of H84T intraperitoneally are highly protective,
as is H84T administered subcutaneously. Mechanistically, at-
tachment is only somewhat inhibited by H84T, incommensurate
with the overall inhibitory effect of H84T, which was unexpected
based on our observation that wild-type (WT) BanLec inhibits
HIV attachment to cells. Instead, H84T, which can bind to HA,
is internalized into the late endosomal/lysosomal compartment
and inhibits the HA-mediated step of fusion with the endosome.
Taken together, these studies reveal that H84T is efficacious
against influenza virus in vivo, even when given up to 72 h after
challenge, and that it inhibits virus–endosome fusion, under-
scoring its potential use as a new broad-spectrum antiinfluenza
agent with a mechanism of action that is quite distinct from that
of the currently available inhibitors.
Results
H84T Is Active Against Oseltamivir-Resistant and Influenza B Viruses
and Synergizes with Oseltamivir In Vitro. Our previous work dem-
onstrates that H84T has robust activity against diverse influenza
viruses in vitro, including A/California/04/2009 (H1N1)pdm09,
A/California/07/2009 (H1N1)pdm09, A/New York/18/2009 (H1N1)
pdm09, A/Perth/16/2009 (H3N2), A/Duck/MN/1525/1981 (H5N1),
and the 1918 H1N1 pandemic strain, with half-maximum effective
concentration (EC50) values of 1 to 4 μg/mL (∼32 to 130 nM)
versus H1N1 virus, 0.06 to 0.1 μg/mL (∼2 to 3 nM) versus H3N2
virus, and 5 to 11 μg/mL (∼160 to 350 nM) versus H5N1 virus (12).
Antiinfluenza activity is dependent on carbohydrate binding, as
the D133G BanLec mutant lacking carbohydrate-binding activity
has no antiinfluenza activity. Because influenza strains resistant to
the standard-of-care therapy, oseltamivir, do circulate in certain
years (7, 14, 15), we sought to evaluate whether H84T is effective
against oseltamivir-resistant viruses. Indeed, H84T inhibited rep-
lication of A/Mississippi/3/2001-H275Y (H1N1), a strain reported
to be oseltamivir-resistant (16–18), in Madin-Darby canine kid-
ney (MDCK) cells, with an EC90 value of 0.074 μg/mL (2.4 nM),
as compared to >100 μg/mL for oseltamivir. H84T treatment
also decreased spreading infection of two other oseltamivir-
resistant viruses in tissue culture, A/Texas/12/2007 (H3N2) and
A/Louisiana/08/2013 (H1N1)pdm09 (SI Appendix, Fig. S1), in which
NA inhibitor resistance is conferred by the E119V and H275Y
mutations, respectively, and adamantane resistance conferred by
the S31N mutation (19, 20). Thus, H84T is highly effective even
against oseltamivir- and adamantane-resistant strains.
As combination therapy with both oseltamivir and H84T could
be a potential strategy to treat oseltamivir-susceptible strains, we
sought to determine whether synergy exists between oseltamivir
and H84T. Treatment of MDCK cells infected with A/California/
07/2009 (H1N1)pdm09, A/Perth/16/2009 (H3N2), A/Duck/MN/
1525/1981 (H5N1), and B/Brisbane/60/2008 with both oseltami-
vir and H84T resulted in a virus yield reduction that exceeded
one log10 when compared to either individual drug alone, iden-
tifying possible synergy between oseltamivir and H84T for all
four viruses tested (21) (SI Appendix, Tables S1–S4). We further
examined the effect of the drug combination using 3D analysis
(MacSynergy II) (22) and found that the combination of oseltamivir
and H84T has minor but significant synergy against both
A/California/07/2009 (H1N1)pdm09 and A/Perth/16/2009 (H3N2)
(SI Appendix, Figs. S2 and S3). Thus, H84T shows some, but not
striking, synergy with oseltamivir.
Since influenza B infections cannot be distinguished clinically
from influenza A infections (23), antiinfluenza agents that have
activity against both influenza A and B are particularly attractive
for empiric treatment of influenza-like illnesses. We therefore
sought to evaluate whether H84T is efficacious against influenza
B virus infection. We found that H84T has EC50 concentrations
by neutral red assay of 0.15 and 0.33 μg/mL (∼4.8 and 11 nM)
against influenza B viruses B/Brisbane/60/2008 (Victoria lineage)
and B/Florida/4/2006 (Yamagata lineage), respectively, and re-
duces spreading infection of B/Brisbane/60/2008 in MDCK cells
(SI Appendix, Fig. S4), indicating that H84T is indeed active
against influenza B viruses and has promise as an antiinfluenza A
and B agent.
Intranasal Administration of H84T Protects Against Lethal H3N2
Influenza Virus Infection. We previously reported that intranasal
administration of H84T protects mice against otherwise lethal
H1N1 influenza virus infection (12). To assess whether H84T is
also efficacious against another influenza virus strain in vivo, we
inoculated C57BL/6J mice via aerosol with a lethal dose of
A/Hong Kong/8/1968 (H3N2) influenza virus and treated them
with 0.1 mg/kg of H84T intranasally once daily for 5 d beginning
4 h postinfection (SI Appendix, Fig. S5). Greater than 80% of
H84T-treated mice survived otherwise lethal influenza virus in-
fection, as compared to <10% of placebo-treated animals, extend-
ing the results of our previous study and indicating that H84T has
robust activity against the two major contemporary subtypes of in-
fluenza A in vivo.
H84T, but Not WT BanLec, Is Well-Tolerated In Vivo.Given that H84T
is highly efficacious against influenza infection in vitro and in vivo
via intranasal administration, we sought to further characterize its
safety and efficacy in vivo when administered systemically. In
BALB/c mice, we found that intraperitoneal administration of WT
BanLec in two 50-mg/kg doses 1 mo apart resulted in prolonged
injection site lesions, characterized as erythematous papules up to
a centimeter in size, in 60% of the mice lasting for up to 23 d
postinjection (Fig. 1A); piloerection of back hair for up to 4 d
postinjection in all of the mice (Fig. 1B); and reversible but
notable weight loss of an average of ∼10% of body weight (Fig.
1C). These findings support in vivo the in vitro finding that WT
BanLec is mitogenic and give a stark description of how mitoge-
nicity manifests in vivo. In clear contrast, intraperitoneal admin-
istration of H84T was very well tolerated, resulting in no injection
site lesions, no piloerection of back hair, and no weight loss upon
administration of either dose, similar to administration of D133G
BanLec, which in vitro lacks both mitogenicity and antiviral ac-
tivity due to a mutation in the carbohydrate-binding site and so
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was not expected to elicit an inflammatory reaction. Thus, H84T
appears to be nonmitogenic both in vitro and in vivo, in contrast to
WT BanLec, which is poorly tolerated in mice, consistent with its
mitogenicity in vitro.
H84T Distributes to the Lung. We next determined the pharmaco-
kinetic profile of H84T in mice dosed intraperitoneally with 5,
15, and 50 mg/kg of the lectin in a single injection by measuring
the concentration of H84T postinjection in both the plasma and
lung (SI Appendix, Fig. S6A). H84T showed a dose-dependent
increase in total drug exposure in plasma with a terminal half-life
ranging from 33.5 to 238 h in plasma and from 25 to 32 h in the
lung (SI Appendix, Tables S5 and S6). Total exposure levels (AUClast)
of H84T in the lung, a key target organ for influenza treatment,
exceed plasma levels significantly, but in a nonlinear fashion, with
an ∼200-fold increase at 5 mg/kg, ∼100-fold at 15 mg/kg, and ∼30-
fold at 50 mg/kg. Lower doses deliver a greater portion of H84T
to the lung and might allow for minimizing systemic exposure if
Fig. 1. Systemic H84T is very well tolerated in mice. BALB/c mice were injected intraperitoneally with two 50-mg/kg doses of WT, H84T, or D133G BanLec
administered 1 mo apart (n = 10 per group). Injection site lesions (A) and appearances (B) were scored, and weight measured (C) for all mice for 59
d postinjection. In C, the data represent the mean for all mice in each group and error bars the SEM.
2124 | www.pnas.org/cgi/doi/10.1073/pnas.1915152117 Covés-Datson et al.
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proven efficacious. Furthermore, H84T remains in the lung for
greater than 72 h at the dose levels tested (SI Appendix, Fig.
S6A). The long terminal half-life and prolonged presence of
H84T in the lung raises the possibility that H84T could be ad-
ministered as a single-dose treatment, or at least be given at long
intervals. In a parallel assessment of the distribution of H84T, we
found that H84T distributes to the lung, as well as the liver and
spleen, but not to the brain or kidney in mice dosed intraperi-
toneally with 50 mg/kg of H84T (SI Appendix, Fig. S6B).
Therapeutic Administration of H84T Protects Against Lethal Influenza
Virus Infection. To assess the therapeutic potential of H84T de-
livered systemically, we inoculated BALB/c mice intranasally
with a lethal dose of influenza and treated them with H84T
delivered intraperitoneally once daily for 5 d beginning 4 h
postinoculation (Fig. 2A). All mice treated with H84T at 5 mg/kg
once daily survived, as compared to <10% of placebo-treated
animals. Furthermore, mice treated at 5 mg/kg once daily up
to 24 h postchallenge all survived, as compared to ∼90% treated
with oseltamivir twice daily and <20% treated with PBS. Strik-
ingly, 80% of mice were still protected when treatment began
48 or 72 h postchallenge (Fig. 2B). A key remaining question
was whether H84T-treated mice would mount an antibody re-
sponse to the therapeutic protein that would limit the efficacy of
future H84T treatment (24). We found that mice do develop
antibodies against H84T (SI Appendix, Fig. S7), consistent with
the finding by others that people develop antibodies to WT
BanLec (25) and with our finding that human sera from three
healthy donors also contained antibodies to H84T (SI Appendix,
Fig. S8). However, even mice with anti-H84T antibodies gener-
ated at a time of prior H84T administration are 100% protected
from lethal influenza infection by H84T treatment (Fig. 2C).
These mice also suffered no histological or biochemical damage to
the lung, liver, spleen, blood, or other organs.
H84T confers robust antiinfluenza protection when delivered
intraperitoneally, but in a clinical setting intravenous adminis-
tration, which is analogous to intraperitoneal administration, of
H84T would likely be limited to hospitalized patients. On the
other hand, subcutaneous administration of H84T, if efficacious,
would provide the important advantage of being feasible in the
outpatient setting. We therefore examined whether subcutane-
ous administration of H84T conferred protection against lethal
influenza virus infection in mice (Fig. 2D). BALB/c mice were
inoculated intranasally with a lethal dose of influenza virus and
survival of the mice monitored after treatment with one or two
50-mg/kg doses of H84T. H84T provided 100% protection from
challenge when administered in a two-dose regimen at 4 h pre-
infection and 4 d postinfection, as compared to <10% survival in
the placebo-treated group. In addition, two doses of H84T
provided 60% protection when administered at 24 h and 96 h
(4 d) postinfection, and a single dose at 24, 48, or 72 h provided
50% protection. Oseltamivir, used as the positive control, pro-
tected 70% of mice when administered twice daily for 5 d starting
48 h postinfection. Thus, it appears that subcutaneous administra-
tion of H84T holds therapeutic promise as well.
H84T Binds to HA Specifically, but Only Minorly Decreases Attachment
of Influenza Virus. A detailed mechanistic understanding of H84T’s
ability to inhibit influenza replication is key to developing it as a
potential new therapeutic (26, 27). H84T is known to bind to high-
mannose structures and perhaps other types of N-glycans such as
can be found on the influenza virus glycoproteins HA and NA. To
ascertain whether H84T interacts with HA, we performed ELISAs
using recombinant HA from A/California/07/2009 (H1N1)pdm09
and A/Perth/16/2009 (H3N2) derived from baculovirus, with the
D133G BanLec mutant as a control, as it does not bind carbo-
hydrates. Insect-derived glycoproteins are glycosylated in a distinct
manner as compared to mammalian glycoproteins, in that they
lack high-mannose N-glycans and instead contain paucimannose
N-glycans (28). However, it should be noted that high-mannose
and paucimannose N-glycans are structurally similar, with pauci-
mannose N-glycans containing terminal mannose residues like
high-mannose N-glycans, although fewer of them. Furthermore,
BanLec is known to interact with paucimannose N-glycans (29),
Fig. 2. Systemic H84T treatment is highly efficacious against lethal influenza virus infection in mice. (A–C) Therapeutic efficacy of H84T administered in-
traperitoneally in BALB/c mice challenged intranasally with two times the 50% mouse lethal dose of A/WSN/HA(NC/2099-N225G)/1933 (H1N1). (A) Survival of
mice following intraperitoneal treatment with H84T (0.15–5 mg/kg) once daily for 5 d beginning 4 h postchallenge. (B) Survival of mice following in-
traperitoneal treatment with H84T (5 mg/kg) once daily for 5 d beginning 4, 24, 48, or 72 h postchallenge, or treatment with oseltamivir (10 mg/kg) beginning
4 or 72 h postchallenge. (C) Survival of mice following intraperitoneal treatment with H84T (50 mg/kg) on a single occasion 21 d before challenge, then once
daily for 5 d (5 mg/kg/d) beginning 4 h postchallenge. Placebo mice received PBS 21 d prechallenge and once daily for 5 d beginning 4 h postchallenge.
(D) Therapeutic efficacy of H84T administered subcutaneously in BALB/c mice challenged intranasally with a lethal dose of A/WSN/HA(NC/2099-N225G)/1933
(H1N1). Survival of mice following subcutaneous treatment with a regimen of either one or two 50-mg/kg doses of H84T within 4 d postinfection. *P < 0.05,
**P < 0.01, ***P < 0.001, and ****P < 0.0001. Kaplan–Meier survival curves for A to D were compared by the log-rank (Mantel–Cox) test followed by pairwise
comparison using the Gehan–Breslow–Wilcoxon test.
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although not as strongly as with high-mannose N-glycans. There-
fore, we reasoned that determining whether H84T could bind to
baculovirus-derived HA would be an informative first step. We
observed that H84T binds HA in a concentration-dependent
manner, and D133G shows much reduced binding to HA (SI
Appendix, Fig. S9A), which suggests that H84T could potentially
inhibit HA-mediated steps and that carbohydrate binding activity
is important for binding to HA. To further assess whether binding
to HA was dependent on carbohydrate binding, we performed a
series of competition ELISAs with several different carbohydrates.
The known H84T ligand methyl α-D-mannopyranoside was able
to inhibit binding of H84T to HA in a concentration-dependent
manner (SI Appendix, Fig. S9B). Unsurprisingly, it took a relatively
large concentration of the sugar to compete for HA binding since
there are predicted to be a large number of interaction sites for
H84T on the HA glycans (13, 30). A higher concentration of the
sugar was required to inhibit binding to H3 than to H1 HA. The
binding to HA was specific, since galactose, known to not be a
ligand for H84T (12), was not able to inhibit binding to HA (SI
Appendix, Fig. S9C). Yeast mannan, which contains more man-
nose residues than does methyl α-D-mannopyranoside (31), was
able to inhibit binding to HA at 10-fold lower concentrations (SI
Appendix, Fig. S10).
The above experiments suggested that H84T does indeed bind
to HA, but given the differences between insect and mammalian
glycosylation, we sought to determine whether H84T could also
bind to viral-derived HA produced in mammalian cells, and
furthermore, to which subunits it might bind. Influenza HA is
comprised of two subunits; HA0 is the full-length peptide that,
upon activation of the virus by cellular proteases, is cleaved into
HA1, which forms the head group, and HA2, which forms most
of the stalk. We performed lectin blot analysis with viral lysates
from three strains (A/Florida/3/2006 [H1N1], A/Perth/16/2009
[H3N2], and B/Brisbane/60/2008) produced in chicken egg cul-
ture (Fig. 3). Lectin blot analysis is similar to Western blot
analysis, except that blots are probed first with lectins, after
which primary and secondary antibodies are directed against the
lectins in order to determine with which blotted proteins a par-
ticular lectin interacts. Viral proteins from the lysates were in-
cubated overnight with either PNGase F, a bacterial enzyme that
cleaves all N-glycans from glycoproteins, or PBS (mock), after
which the lysates were resolved by reducing SDS/PAGE and
blotted. Blots were then probed with H84T prior to antibody
detection of BanLec (Fig. 3A and SI Appendix, Fig. S11). When
the proteins were incubated with PBS, H84T bound to both HA0
and HA1 in all three strains, but did not appear to bind to HA2
in any of the strains. In contrast, when the proteins were in-
cubated with PNGase F, the proteins migrated faster, demon-
strating that deglycosylation had occurred, and there was a
marked reduction of H84T binding to HA0 and HA1, indicating
that H84T binding to HA is carbohydrate-dependent. The per-
centage of binding of H84T to HA1 in the PNGase F- versus
mock-treated group for each strain was calculated by comparing
band intensity, with mock-treated set at 100% (Fig. 3B). Not all
binding was abolished, likely due to incomplete deglycosylation
by PNGase F, although some lectins are also known to interact
with molecules in a nonglycan-mediated manner (32). D133G
showed dramatically less binding than did H84T (Fig. 3 C and
D), underscoring that the ability to bind carbohydrates is im-
portant for binding to HA.
HA mediates both early and late stages of the virus life cycle,
including attachment and entry, fusion, and assembly, whereas
NA, another potential target for H84T, primarily mediates late
stages, including assembly and budding (9). To understand whether
H84T exerts its primary inhibitory effect against influenza virus
replication early or late in the influenza virus life cycle, we
assessed whether viral protein expression was reduced by H84T.
Arbidol (ARB), a viral fusion inhibitor that locks HA in a
nonfusogenic conformation (33), was used as a positive control
for inhibition of early-stage infection. A dose-dependent reduc-
tion in viral protein expression was observed at 5 h postinfection
(hpi) with A/WSN/1933 (H1N1) (Fig. 4 A and B), suggesting
that H84T inhibits a step at or before viral protein translation.
Inhibition was dependent on carbohydrate binding, as D133G
did not block viral protein expression. H84T also inhibited a step
at or before protein translation 5 hpi with a virus pseudotyped
with the HA and NA of A/Colorado/15/2014 (H3N2), a strain
representative of the 3C.2a clade of H3N2 viruses that encom-
passed the majority of the ∼69% of clinical influenza infections
caused by H3N2 strains in the 2017 to 2018 season, for which
vaccine effectiveness was only ∼25% (2) (Fig. 4 C and D). To
ensure that the decrease in viral protein expression observed
could not be attributed to toxicity, we measured cytotoxicity of
H84T on MDCK cells. At 24 h posttreatment, there was no
decrease in cell viability at the EC50 concentration for H1N1
virus (∼32 to 130 nM), and minimal decreases above it, sug-
gesting that cytotoxicity could not account for the observed de-
crease in viral protein expression (SI Appendix, Fig. S12).
We next sought to further delineate the step at which H84T
inhibits influenza virus replication, hypothesizing that H84T
would inhibit influenza virus at the attachment or fusion steps,
since we previously found that those (especially the former) are
the steps at which WT BanLec inhibits HIV infection (30). To
investigate whether attachment was decreased by H84T, we in-
fected MDCK cells for 1 h at 4 °C with A/WSN/1933 (H1N1)
that had been preincubated for 30 min with concentrations of
H84T from 1 to 10,000 nM, the timing and temperature allowing
the virus only to attach but not progress to postattachment steps.
After washing cells to remove excess virus, we collected the cells
and extracted whole-cell RNA. We then measured the amount of
cell-associated virus, which represents the amount of virus that
Fig. 3. H84T binds to virus-derived HA. (A) Lectin blot. Virus particles from
A/Florida/3/2006 (H1N1), A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008
were lysed for protein extraction. Proteins were incubated with PNGaseF to
remove N-glycans or with PBS (mock) overnight, then resolved by reducing
SDS/PAGE and blotted. Blots were incubated with 100 nM H84T, followed by
primary and secondary antibody incubations to detect BanLec bound to viral
proteins. Note that the lower band seen in the influenza B lanes does not
appear to be HA2 as it does not run at the correct size. Mol. weight, mo-
lecular weight. (B) Percent binding of H84T to PNGase- versus mock-treated
HA1 in A, relative to mock-treated set at 100%. Data in A and B are rep-
resentative of three independent experiments. *P < 0.05, **P < 0.01, ***P <
0.001, as compared to the mock-treated group. Error bars denote the SEM.
+, PNGase F-treated; −, mock-treated. (C) Lectin blots were performed as in A,
without PNGase F digestion. Blots were incubated with 100 nMH84T or D133G
BanLec. Data are representative of three independent experiments. (D) Pro-
teins were resolved as in C but not transferred and gels stained with a
Coomassie-based reagent.
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has undergone attachment, by qRT-PCR. We observed that cells
infected with virus that had been preincubated with H84T
showed a minor decrease in the amount of cell-associated virus,
to a much lesser extent than did cells infected with virus that had
been preincubated with the monoclonal antibody H17-L19, known
to inhibit attachment of this strain (34) (SI Appendix, Fig. S13A).
In parallel, H84T also could not inhibit hemagglutination of tur-
key red blood cells, which depends on interactions between HA
and red blood cells that are akin to those between HA and the cell
during attachment, by the virus (SI Appendix, Fig. S13B). These
results suggest that attachment is only minorly inhibited by H84T,
which was surprising as this was the step at which HIV was pre-
dominantly inhibited by WT BanLec (30).
H84T Inhibits Endosomal Fusion of Influenza Virus. Given that in-
hibition of attachment does not appear to be the major mecha-
nism of action of H84T, we next investigated whether fusion is
decreased by H84T (Fig. 5). Dequenching of the fluorescent
membrane probe R18 from R18-labeled virus was measured in
MDCK cells pretreated with the fusion inhibitor ARB, as a pos-
itive control, or H84T. When incorporated into the viral mem-
brane at a high molarity, R18 quenches itself, but when fusion of
the viral membrane with the plasma membrane is induced by a low
pH fusion buffer, R18 diffuses laterally across the much larger
plasma membrane, becoming dequenched and fluorescing (35–
37). Triton X-100, as a detergent, induces maximal dequenching
and the highest fluorescence of R18. Labeled virus was allowed to
attach to cells in the presence of ARB or H84T before the addi-
tion of fusion buffer, after which fluorescence dequenching was
measured. In cells incubated with virus, fusion buffer alone in-
creased fluorescence to levels near to those from Triton X-100–
treated cells, indicating that fusion with the plasma membrane had
occurred. Treatment with 40 μM ARB or 1 and 10 μM H84T sig-
nificantly reduced fluorescence dequenching upon exposure to low
pH, which suggests that H84T may act by inhibiting viral fusion.
If fusion of influenza virus is inhibited by H84T, we reasoned
that the next step in the virus life cycle would also be inhibited,
namely uncoating of the viral ribonucleoproteins. With uncoating,
the viral matrix protein (M1), which forms the scaffolding between
the viral membrane and the viral ribonucleoproteins, dissociates
from its prefusion location beneath the membrane and disperses
throughout the cytoplasm of the cell. Detection of diffuse M1 by
immunocytochemistry has thus been used at early infection time
points (2.5 h, before protein translation leads to the production of
Fig. 4. H84T prevents influenza virus protein expression in MDCK cells. MDCK cells were pretreated for 1 h with H84T (0.1, 1, or 10 μM in A; 0.05, 0.1, or 1 μM
in C), 10 μM D133G, or 40 μM of the fusion inhibitor ARB and infected with A/WSN/1933 (H1N1) (A) or A/Colorado/15/2014 (H3N2) (C) (MOI = 0.5) for 5 h at
37 °C. (A and C) Representative immunofluorescent micrographs of influenza A antigen staining (green) and nuclei (blue) 5 h postinfection. Data for A and C
are representative of three and four independent experiments, respectively. Scale bars indicate 100 μm. (B and D) Quantitation of the number of cells with
influenza protein-positive nuclei per field, as assessed by a trained observer in a blinded fashion. Statistical analyses were performed by t test. *P < 0.05, **P <
0.01, ***P < 0.001, and ****P < 0.0001, as compared to the infected, untreated group. Error bars denote the SEM.
Fig. 5. H84T inhibits influenza virus fusion. MDCK cells were pretreated for
1 h at 37 °C with 1 or 10 μM H84T or 20 or 40 μM of the fusion inhibitor ARB
and incubated with octadecyl R18-labeled A/WSN/1933 for 1 h at 4 °C to
allow attachment only. Excess virus was removed and virus fusion with the
cell membrane was triggered at 37 °C using pH ∼5.25 fusion buffer. Fluo-
rescence dequenching of R18 was monitored on a microplate fluorometer
with excitation and emission wavelengths of 560 and 590 nm, respectively.
Maximal dequenching was achieved with 1% Triton X-100 set at 100%. Bars
represent the mean values from duplicate wells from two independent ex-
periments and error bars represent the SEM. Statistical analyses were per-
formed by t test. *P < 0.05, **P < 0.01, comparing groups indicated by
brackets.
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more M1) to determine in which cells uncoating, and thus fusion
immediately before it, has occurred (38). After 2.5 h of infection
with A/WSN/1933 (MOI 0.5), many MDCK cells displayed diffuse
cytoplasmic staining of M1, indicating that uncoating had occurred
in these cells (Fig. 6 A and B). As expected, the number of cells
with diffuse M1 staining was significantly decreased by treatment
with ARB. H84T also reduced the number of cells with diffuse M1
staining in a dose-responsive manner, indicating that H84T pre-
vents events (such as fusion) that occur before (or at) uncoating of
the virus (Fig. 6C). Instead of diffuse M1 staining, virtually all of
the ARB-treated infected cells and increasing numbers of infected
cells treated with H84T in a dose-dependent manner exhibited
perinuclear, punctate staining of M1 (Fig. 6B), consistent with
localization in the late endosome. The reduction in diffuse stain-
ing of M1 was observed both when the cells were pretreated with
H84T and when only the virus was pretreated with H84T, sug-
gesting that preconditioning of cells is not required for H84T to
exert its antiinfluenza activity. We performed these studies with
two more recently circulating strains, A/Florida/3/2006 (H1N1)
and A/Perth/16/2009 (H3N2), and again observed the same de-
crease in diffuse M1 staining and increase in perinuclear punctate
M1 staining with H84T treatment (SI Appendix, Fig. S14). These
results suggest that H84T prevents exit of influenza viruses from
the endosome. Indeed, colocalization between M1 in the M1+
punctae and the late endosomal/lysosomal marker LAMP1 is high
in H84T-treated cells as compared to untreated infected cells
(Fig. 7). These results indicate that uncoating is inhibited by
H84T, consistent with a block at the step of fusion and restriction
of the virus to the endosome.
H84T Is Internalized into the Late Endosomal/Lysosomal Compartment.
Because H84T inhibits fusion between the virus and the endosomal
membrane, we hypothesized that it might be internalized into the
endosome in infected cells, but not in uninfected cells, via binding to
HA. However, interestingly, H84T treatment alone increases the
size of LAMP1+ punctae in cells relative to untreated cells (SI
Appendix, Fig. S15), suggesting that H84T may be internalized
even in the absence of virus, as has been demonstrated for other
lectins (39, 40). As predicted, immunofluorescent staining for
BanLec revealed that H84T is internalized into punctae that
resemble late endosomes/lysosomes (SI Appendix, Fig. S16) in
both infected and uninfected cells; D133G is internalized into
cells to a dramatically lesser extent. To examine whether H84T is
internalized into the late endosomal/lysosomal compartment in
the absence of influenza virus infection, we next treated cells
with His-tagged H84T or D133G and performed immunofluo-
rescent staining for the His tag and LAMP1. Colocalization be-
tween the His tag and LAMP1 was high in H84T-treated cells (SI
Appendix, Fig. S17), indicating that H84T localizes to the late
endosome/lysosome, whereas D133G-treated cells exhibited
minimal His tag staining, consistent with the low degree of
BanLec staining in D133G-treated cells (SI Appendix, Fig. S16).
In rare D133G-treated cells, His tag staining resembled that in
H84T-treated cells and colocalization between the His tag and
LAMP1 was high (SI Appendix, Fig. S17, Inset), suggesting that in
the rare cases that D133G is internalized, it localizes to the same
compartment as does H84T. Given that both M1 and LAMP1, as
well as H84T and LAMP1, colocalize to a high degree in H84T-
treated cells, it is likely that H84T and the virus also colocalize in
the late endosomal/lysosomal compartment, ideally positioning
H84T for inhibition of fusion.
Discussion
Due to their ability to bind to glycan structures, especially high-
mannose preferentially expressed on the surface of pathogenic
viruses, lectins have been considered as potential antiviral ther-
apeutics (41). In the case of influenza, cyanovirin-N (CV-N),
surfactant protein (SP)-A, SP-D, and mannose-binding lectin
Fig. 6. H84T reduces influenza virus uncoating. MDCK cells were pretreated for 1 h with 0.1, 1, or 10 μMH84T, 10 μM D133G, or 40 μM of the fusion inhibitor
ARB and infected with A/WSN/1933 (MOI 0.5) for 2.5 h at 37 °C. (A) Representative immunofluorescent micrographs of M1 antigen staining (green) and nuclei
(blue) 2.5 h postinfection. Scale bars indicate 50 μm. (B) Micrographs of single cells from A, as denoted by the boxes in A. Scale bars indicate 5 μm. Data for
A and B are representative of 15 independent experiments. (C) Quantitation of the number of cells with diffuse cytoplasmic M1 staining per field, as assessed by
a trained observer in a blinded fashion. Statistical analyses were performed by t test. *P < 0.05 and **P < 0.01, as compared to the infected, untreated group.
Error bars represent the SEM.
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are among the lectins shown to have activity in vitro or in vivo
(42–44). We have demonstrated that an engineered banana
lectin, H84T BanLec, is highly active against an array of in-
fluenza virus strains. While it is somewhat difficult to compare
the overall sensitivity of influenza viruses to the different lectins
without head-to-head comparisons, H84T BanLec would appear
to be similar in vitro and equal to, or perhaps better than most
previously tested lectins (e.g., CV-N EC50 = 0.005 to >10 μg/mL
against tested influenza virus strains). It is notable that H84T is
quite broad-spectrum, capable of inhibiting multiple oseltamivir-
resistant as well all other influenza virus strains tested in this and
our previous study (12); H84T inhibits both influenza A and B
type viruses and a representative of the currently circulating
3C.2a clade of H3N2 viruses, which proved especially deadly in
the 2017 to 2018 Northern Hemisphere influenza season (2). The
finding that there is some synergy between H84T and oseltamivir
raises the possibility of combination therapy, which might be more
effective than single agents alone and limit the development of
resistance.
Paralleling the reduced mitogenicity of H84T compared to
WT BanLec that we previously demonstrated in vitro, systemic
administration of H84T does not result in the robust inflam-
matory response seen after administration of the WT lectin, in-
dicating that we have truly removed mitogenicity from H84T by
substituting one specific amino acid for another. Mitogenicity
has primarily been addressed as an in vitro concept, with studies
examining mitogenicity of lectins in vivo focusing on local rather
than systemic effects (45). However, through our study, we have
been able to characterize in vivo the effects of a systemically
delivered mitogenic versus nonmitogenic lectin. Lessening mi-
togenic activity of BanLec via the H84T mutation has removed a
major hurdle in the development of an antiviral lectin for clinical
use, since mitogenicity has been viewed as the biggest drawback
for most lectins (11). In addition, we have shown that H84T
BanLec is very safe when delivered by the intraperitoneal and
subcutaneous routes, with this and our previous study (12)
showing that it is also safe when administered intranasally.
H84T delivered systemically by the intraperitoneal route pos-
sesses a long terminal half-life, indicating that infrequent or even
single dosing could potentially be efficacious, which would be
clinically advantageous. However, intravenous administration, which
is largely analogous to intraperitoneal administration in the
mouse, would not be ideal for all clinical situations (e.g., treating
outpatients with influenza virus infections). Oral administration is
not a feasible clinical strategy, as it is known that alimentary lectins
do not effectively distribute to the blood (46–48), but as we have
shown, subcutaneous and intranasal administration are efficacious
and have potential as eventual treatments in the outpatient set-
ting. Thus, H84T BanLec shows promise for use in both hospi-
talized patients and outpatients. It is notable that administration
of H84T can be delayed for up to 72 h and still offer 80% pro-
tection by the intraperitoneal route and 50% protection by the
subcutaneous route. People have antibodies against banana lectin
(25), which means that they would potentially develop or already
possess antibodies against H84T, but this is not expected to limit
activity given that the efficacy of H84T against influenza infection
was not lessened in mice with anti-H84T antibodies. It is worth
pointing out that the class of antibody that people develop against
bananas is IgG4 (25), which is widely thought to be tolerogenic
and so potentially less likely to disrupt therapeutic efficacy of
H84T. Of course, whether humans develop therapeutically limit-
ing antibodies to H84T would ultimately need to be determined
in humans.
Our work indicates that H84T binds to HA specifically, as
binding to baculovirus-derived HA can be inhibited by a known
ligand of BanLec but not by a noninteracting monosaccharide
and as carbohydrate digestion by PNGase F reduces binding to
virus-derived HA. Furthermore, we demonstrate that H84T functions
as an antiinfluenza agent primarily via fusion inhibition. Carbo-
hydrate binding is essential for both binding and fusion inhibi-
tion, as the carbohydrate binding site mutant D133G does not
bind as efficiently and is not inhibitory to fusion. A key
question to address was where HA might be bound by H84T, as
both its head (HA1) and stalk (HA2) regions are glycosylated
with high-mannose type N-glycans (13), among other glycans,
which are ligands for H84T. Neutralizing antibodies that func-
tion as fusion inhibitors typically bind the stalk of HA (49–51),
which contains the fusion peptide and other components nec-
essary for fusion (52). However, work by others indicates that an
inhibitor that binds to the head of HA can target fusion (53) and
it is known that the antiinfluenza lectin cyanovirin-N binds HA1
(43), so it was not wholly unexpected that H84T would bind
HA1. A potential limitation of H84T is that it may require that
its target be glycosylated and pandemic strains are sometimes
less heavily glycosylated than seasonal strains, but some glyco-
sylation is virtually always present, even in pandemic strains (13).
Interestingly, the number of glycosites that a certain strain pos-
sesses seems to correlate with the EC50 concentration of H84T
against that strain. Contemporary H3 viruses have more glyco-
sites than contemporary H1 viruses (13) and H84T has a lower
EC50 concentration against the former strains, which correlates
with the higher amount of methyl α-D-mannopyranoside needed
to compete for binding to H3 versus H1 HA. In addition, the
amount of binding to strains as determined by lectin blot gen-
erally correlated with the EC50 concentrations of H84T against
those strains, with the most binding to the H3N2 strain, followed
by binding to influenza B, then the H1N1 strain. Of course,
multiple other strains of each subtype would need to be evalu-
ated to further clarify this issue. It is presently not possible to
assess whether binding of H84T correlates with the number of
high-mannose N-glycans in particular on certain HA mole-
cules, as the number of high-mannose glycans on specific HAs
cannot be predicted by the sequence of the protein and has to be
Fig. 7. H84T restricts influenza virus to the late endosomal/lysosomal com-
partment. (A) Representative immunofluorescent micrographs of M1 (green)
and LAMP1 antigen staining (red) and nuclei (blue). Following 1 h pre-
treatment with H84T (10 μM), MDCK cells were incubated with A/WSN/1933
(H1N1) at 4 °C for 1 h to allow only for attachment, excess virus was re-
moved, treatment-containing medium was replaced, and the cells were in-
cubated at 37 °C for an additional 3 h. The second and fourth rows are
micrographs of one or two cells from the first and third rows, respectively,
indicated by the arrows. Data are representative of five independent ex-
periments. Scale bars indicate 50 μm in the first and third rows and 10 μm in
the second and fourth rows. (B) Quantitation of the percent of M1+ punctae
that are also LAMP1+ (percent overlap). Statistical analyses were performed
by t test. ****P < 0.0001, as compared to the infected, untreated group.
Error bars represent the SEM.
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empirically determined (54), but overall it appears that binding
to HA by H84T correlates with the number of glycans on HA.
H84T treatment, regardless of infection status, enlarges the
LAMP1+ compartment, consistent with the observation that many
lectins are internalized by endocytosis and that some induce the
formation of large lysosomes (39, 40). H84T, and to a much lesser
extent D133G, localize to the late endosome/lysosome. Although
H84T is internalized into the endosomal compartment and en-
larges it, the fact that fusion at the plasma membrane is inhibited
by H84T (Fig. 5), in addition to uncoating at the endosomal
membrane, suggests that the antiinfluenza activity of H84T does
not depend primarily on alteration of the endosomal compart-
ment. Consistent with these observations, preconditioning of the
endosomal compartment with H84T is not required for viral in-
hibition, since either cells or virus can be pretreated with H84T
and the lectin is still highly active against uncoating. We therefore
posit that binding of H84T to HA is important for the inhibitory
effect of H84T. We propose a model in which H84T, internalized
in both the presence and absence of virus, likely by endocytosis,
accumulates in the late endosomal/lysosomal compartment where
fusion occurs and is thus positioned at a key watch point to in-
teract with HA and thereby prevent entry of virus into the cyto-
plasm. Since H84T disrupts fusion of the virus and prevents its
release into the cytoplasm, it is reasonable to think that the virus
might be degraded once it reaches the lysosome, accounting for
the ability of H84T to decrease influenza virus replication overall.
Our data demonstrate that H84T BanLec has potential as a
new antiviral against influenza viruses. It is very well tolerated
and nonmitogenic in vivo and is highly efficacious against oth-
erwise lethal influenza virus infection via three distinct routes of
administration, even when treatment is delayed. H84T is highly
broad-spectrum in that it inhibits replication of all oseltamivir-
resistant and -sensitive strains and all influenza A and B strains
tested, highlighting its promise as an empiric drug for influenza
illness, which will be critically needed in the event of a new
pandemic influenza virus or increasing resistance to neuramini-
dase inhibitors. H84T is broad-spectrum not only in its antiin-
fluenza activity, but also in the sense that it inhibits HIV and
hepatitis C virus as reported previously (12), and Ebola (55),
among other viruses. The present study, along with our previous
work, underscores the value of engineering antiviral lectins to be
nonmitogenic and safe in vivo, as H84T and perhaps eventually
other similarly engineered lectins could be leveraged as a ther-
apeutic arsenal against a diverse array of viruses.
Materials and Methods
H84T and D133G BanLec Purification. Recombinant His-tagged H84T and
D133G were prepared from Eschrichia coli as previously described (12), ex-
cept that non–His-tagged H84T, which was used in experiments unless
otherwise stated, was prepared using a Sephadex G-75 column instead of a
Ni-NTA agarose column, as described in SI Appendix.
Cells, Viruses, and Antiinfluenza Antibodies. MDCK cells were maintained in
DMEM (Gibco) supplemented with 10% FBS and 1% penicillin/streptomycin
at 37 °C in 5% CO2. Influenza virus infection was performed on monolayers
of MDCK cells in virus growth buffer (DMEM supplemented with 0.187%
BSA and 25 mM Hepes). Supernatant from 293T cells transfected with eight
influenza gene plasmids was used to propagate A/WSN/33 (H1N1) on MDCK
cells, as previously described (56). Recombinant virus containing HA and NA
genes from A/Colorado/15/2014 (H3N2) and other genes from A/Puerto Rico/
8/1934 (H1N1) was engineered by reverse genetics and propagated on
MDCK-SIAT1 cells to limit adaptation and glycan changes. Additional
strains and antiinfluenza antibodies are indicated in figure legends and in
SI Appendix.
ELISA. For ELISA, 96-well ELISA plates (Thermo Fisher Scientific) were coated
overnight with 100-ng recombinant H1 or H3 HA proteins from Influenza
A/California/07/2009 (H1N1)pdm09 and Influenza A/Perth/16/2009 (H3N2), re-
spectively, produced in baculovirus, for determination of H84T binding to HA.
To determine whether human sera contained anti-H84T antibodies, 100 ng of
H84Twere used to coat plates. ELISA experiments were performed as described
in SI Appendix.
Lectin Blot Analysis. Lectin blot analysis was performed as described previously
(57) and as described in the legend of Fig. 3. Further details are provided in
SI Appendix.
Virus Infection and Immunofluorescence Staining. MDCK cells were plated in
eight-well chamber slides, pretreated for 1 h with 0.05 to 10 μMH84T, 10 μM
D133G, or 40 μM ARB, and infected at 37 °C with A/WSN/1933 (H1N1),
A/Perth/2009 (H3N2), or A/Florida/2006 (H1N1) at a multiplicity of infection
(MOI) of 0.5 in the presence of H84T, D133G, or ARB. Where indicated, virus
alone (rather than cells) was pretreated with H84T, D133G, or ARB and
uncoating examined. M1/LAMP1 colocalization studies were performed as
described in Fig. 7. Spreading infections of B/Brisbane/60/2008 were per-
formed following pretreatment, removal of excess virus following 1 h of
incubation, and replacement of treatment-containing medium at MOI =
0.05 for 16 to 18 h. Infected cells were washed twice in virus growth buffer
and once in PBS before fixation in 2% PFA/PBS. Immunofluoresence assays
were then performed as described in SI Appendix.
Neutral Red Assay for Assessment of Antiinfluenza B Activity. Neutral red as-
says were performed to determine the 50% effective concentrations (EC50)
of H84T against B/Brisbane/60/2008 (Victoria lineage) and B/Florida/4/2006
(Yamagata lineage) and 50% cytotoxic concentration (CC50) on MDCK cells,
as described in SI Appendix.
In Vitro Cytotoxicity in MDCK Cells.Monolayers of MDCK cells in 96-well plates
were treated for 24 h with H84T or D133G BanLec (0 to 15 μM) in 100 μL
medium. Cytotoxicity was evaluated by MTT assay (Roche) as described in
SI Appendix.
Cell-Associated Virus Assay. Virus was incubated with 0, 1, 10, 100, 1,000, or
10,000 nM H84T or with 10 μg/mL H17-L19 monoclonal antibody for 30 min
at room temperature, after which the virus-H84T mixture was incubated
with MDCK cells for 1 h at 4 °C, allowing only for attachment. Following
three washes with cold virus growth buffer, cells were collected in TRIzol
reagent (Thermo Fisher Scientific) and whole-cell RNA extracted. To measure
the relative amount of cell-associated virus normalized to GAPDH expres-
sion, qRT-PCR was performed using primers specific to influenza AM1 and to
GAPDH. Primer sequences are provided in SI Appendix.
Hemagglutination Inhibition Assay. Hemagglutination inhibition assays were
carried out using turkey red blood cells as described in SI Appendix.
Virus-Cell Fusion Assay. MDCK cells were pretreated for 1 h with 1 or 10 μM
H84T or 20 or 40 μM of the fusion inhibitor arbidol (ARB, Cayman Chemical),
incubated with octadecyl rhodamine (R18, Sigma-Aldrich)-labeled A/WSN/
1933 virus for 1 h at 4 °C to allow attachment of the virus, then washed three
times in virus growth buffer and once in PBS to remove unbound virus.
Fluorescence dequenching was assessed as previously described (37) and as
described in SI Appendix.
Safety of Intraperitoneal H84T. Eight-week-old female BALB/c mice were in-
jected intraperitoneally with two 50-mg/kg doses of WT, H84T, or D133G
BanLec administered 1 mo apart (n = 10 per group) and weighed and scored
for appearance and injection site lesions.
Pharmacokinetics of Single-Dose Intraperitoneal H84T. To determine the dose-
dependent pharmacokinetic profile of H84T following a single intraperito-
neal dose, groups of 44 5-wk-old male CFW mice were injected intraperi-
toneally on a single occasion with 5, 15, or 50 mg/kg H84T in PBS. Plasma and
lung samples from multiple time points were processed and analyzed by
ELISA as described in SI Appendix.
Distribution of Single-Dose Intraperitoneal H84T. To determine the distribu-
tion of H84T following a single intraperitoneal dose, 15-wk-old female
129svev/B6 mice were injected intraperitoneally with 50 mg/kg H84T. Organs
were harvested at multiple time points and processed for analysis byWestern
blot, as further described in SI Appendix.
Therapeutic Efficacy of Systemic H84T Against Influenza in BALB/c Mice.
Virus. Influenza A/WSN/HA(NC/2099-N225G)/1933 virus, produced as described
in SI Appendix and as described previously (56, 58).
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Experimental design. For the intraperitoneal efficacy study, groups of 10 mice
were treated by the intraperitoneal route, as indicated in Fig. 2. Control
groups included mice treated with 10 mg/kg/d oseltamivir twice daily for 5 d
beginning 4, 24, 48, or 72 hpi, or treated with PBS as placebo (15 mice)
twice daily for the first 5 d postinfection, then once daily for the next 3 d to
match treatment beginning at 4 and 72 hpi. For the subcutaneous efficacy
study, mice were treated by subcutaneous injection using a 50-mg/kg dose of
H84T either once or twice within 4 d postinfection. A group of 10mice was given
oseltamivir by oral gavage twice daily for 5 d with 10 mg/kg of oseltamivir,
starting 48 hpi. Control mice treated with PBS as placebo were dosed according
to the same regimen as H84T. Further details are provided in SI Appendix.
Administration of BanLec for Assessment of Anti-BanLec Antibody Production.
Eight-week-old female BALB/c mice (Taconic) were anesthetized with isoflurane
then injected intraperitoneally with either 50 mg/kg V66D/H84T/A100D BanLec,
a variant ofH84T engineered to increase solubility for biochemical assays, orwith
PBS (n = 5 per group). Twenty-one days later, mice received a second injection
of either BanLec or PBS as before. Mice were euthanized 2 d after the second
administration by the University of Michigan Unit for Laboratory Animal
Medicine. Mouse sera were collected and stored frozen prior to use for de-
tection of anti-BanLec antibodies by ELISA (see ELISA inMaterials andMethods).
Therapeutic Efficacy of Intranasal H84T Against H3N2 Influenza Virus. The ef-
ficacy of intranasal H84T in C57BL/6J mice challenged with A/Hong Kong/8/
1968 (H3N2) was assessed as described in SI Appendix. Virus was delivered by
aerosolization as previously described (59). For each group, n = 12.
Animal Care and Use. Animal studies were conducted in accordance with
institutional policies as described in SI Appendix.
Quantitation of Immunofluorescence Staining. ImageJ was used to quantitate
the number and diameter of punctae in immunofluorescence micrographs,
and the percent overlap of punctae in different color channels, as described in
SI Appendix.
Statistics. All statistical analyses were performed using GraphPad Prism 6 and
7. Specific tests used are noted in figure legends. All t tests performed were
two-tailed.
Materials and Data Availability. H84T must be obtained through material
transfer agreement. All data are available in the main text and SI Appendix.
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